1. Home
  2. MKZR vs REVB Comparison

MKZR vs REVB Comparison

Compare MKZR & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacKenzie Realty Capital Inc.

MKZR

MacKenzie Realty Capital Inc.

HOLD

Current Price

$1.69

Market Cap

4.6M

Sector

N/A

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$0.98

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKZR
REVB
Founded
2012
2020
Country
United States
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
4.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MKZR
REVB
Price
$1.69
$0.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
26.8K
42.0K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.47
52 Week High
$6.99
$3.21

Technical Indicators

Market Signals
Indicator
MKZR
REVB
Relative Strength Index (RSI) 29.74 42.97
Support Level $1.62 $0.80
Resistance Level $4.03 $1.40
Average True Range (ATR) 0.17 0.07
MACD 0.01 -0.00
Stochastic Oscillator 2.54 9.37

Price Performance

Historical Comparison
MKZR
REVB

About MKZR MacKenzie Realty Capital Inc.

Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Share on Social Networks: